COSMOS PHARMACEUTICAL CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,045 JPY | -1.62% |
|
-7.48% | -19.83% |
| Apr. 12 | Cosmos Pharmaceutical's Attributable Profit Up 6.6% in Fiscal Nine Months | MT |
| Apr. 12 | COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 | CI |
Valuation
| Fiscal Period: Mayo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 339,761 | 612,599 | 603,094 | 483,107 | 525,081 | 525,478 | - | - |
| Enterprise Value (EV) 1 | 329,286 | 567,537 | 553,560 | 450,132 | 497,354 | 497,587 | 491,989 | 489,836 |
| P/E ratio | 17.7 x | 28.6 x | 22.2 x | 20.9 x | 22.1 x | 21 x | 19.6 x | 18.2 x |
| Yield | 0.58% | 0.36% | 0.46% | 0.66% | 0.75% | 0.88% | 0.98% | 1.06% |
| Capitalization / Revenue | 0.56 x | 0.9 x | 0.83 x | 0.64 x | 0.63 x | 0.55 x | 0.5 x | 0.46 x |
| EV / Revenue | 0.54 x | 0.83 x | 0.76 x | 0.6 x | 0.6 x | 0.52 x | 0.47 x | 0.43 x |
| EV / EBITDA | 8.73 x | 13.3 x | 11.8 x | 10 x | 10.5 x | 9.59 x | 8.74 x | 8.14 x |
| EV / FCF | 75.9 x | 14.7 x | 65.2 x | -39.1 x | 93.5 x | 95 x | 44.9 x | 54.4 x |
| FCF Yield | 1.32% | 6.78% | 1.53% | -2.56% | 1.07% | 1.05% | 2.23% | 1.84% |
| Price to Book | 2.69 x | 4.21 x | 3.54 x | 2.54 x | 2.49 x | 2.27 x | 2.07 x | 1.9 x |
| Nbr of stocks (in thousands) | 39,599 | 39,599 | 39,599 | 39,599 | 39,599 | 39,629 | - | - |
| Reference price 2 | 8,580 | 15,470 | 15,230 | 12,200 | 13,260 | 13,260 | 13,260 | 13,260 |
| Announcement Date | 7/12/19 | 7/10/20 | 7/12/21 | 7/11/22 | 7/10/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 611,137 | 684,403 | 726,424 | 755,414 | 827,697 | 963,285 | 1,048,607 | 1,132,705 |
| EBITDA 1 | 37,733 | 42,656 | 46,932 | 44,906 | 47,496 | 51,883 | 56,311 | 60,187 |
| EBIT 1 | 24,775 | 29,094 | 33,147 | 29,796 | 30,128 | 32,310 | 34,976 | 37,466 |
| Operating Margin | 4.05% | 4.25% | 4.56% | 3.94% | 3.64% | 3.35% | 3.34% | 3.31% |
| Earnings before Tax (EBT) 1 | 27,139 | 30,402 | 38,596 | 33,048 | 32,773 | 34,892 | 37,661 | 40,391 |
| Net income 1 | 19,185 | 21,435 | 27,156 | 23,155 | 23,797 | 24,987 | 26,833 | 28,914 |
| Net margin | 3.14% | 3.13% | 3.74% | 3.07% | 2.88% | 2.59% | 2.56% | 2.55% |
| EPS 2 | 484.5 | 541.3 | 685.8 | 584.8 | 601.0 | 630.8 | 677.4 | 729.9 |
| Free Cash Flow 1 | 4,337 | 38,505 | 8,494 | -11,523 | 5,321 | 5,237 | 10,954 | 9,008 |
| FCF margin | 0.71% | 5.63% | 1.17% | -1.53% | 0.64% | 0.54% | 1.04% | 0.8% |
| FCF Conversion (EBITDA) | 11.49% | 90.27% | 18.1% | - | 11.2% | 10.09% | 19.45% | 14.97% |
| FCF Conversion (Net income) | 22.61% | 179.64% | 31.28% | - | 22.36% | 20.96% | 40.82% | 31.15% |
| Dividend per Share 2 | 50.00 | 55.00 | 70.00 | 80.00 | 100.0 | 116.7 | 129.5 | 141.1 |
| Announcement Date | 7/12/19 | 7/10/20 | 7/12/21 | 7/11/22 | 7/10/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Mayo | 2020 S1 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 325,269 | 364,175 | 181,729 | 371,138 | 187,747 | 196,529 | 206,122 | 197,894 | 404,016 | 202,286 | 221,395 | 241,653 | 234,777 | 476,430 | 238,881 | 251,848 | 268,050 | 257,562 | 261,694 | 275,844 |
| EBITDA | - | - | 10,066 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 11,965 | 18,292 | 6,423 | 14,979 | 6,918 | 7,899 | 8,900 | 6,485 | 15,385 | 6,782 | 7,961 | 8,990 | 6,846 | 15,836 | 7,902 | 8,571 | 9,746 | 7,522 | 8,635 | 9,001 |
| Operating Margin | 3.68% | 5.02% | 3.53% | 4.04% | 3.68% | 4.02% | 4.32% | 3.28% | 3.81% | 3.35% | 3.6% | 3.72% | 2.92% | 3.32% | 3.31% | 3.4% | 3.64% | 2.92% | 3.3% | 3.26% |
| Earnings before Tax (EBT) 1 | 12,945 | 19,221 | 7,423 | 16,636 | 7,761 | 8,651 | 9,581 | 7,183 | 16,764 | 7,468 | 8,541 | 9,636 | 7,577 | 17,213 | 8,729 | 9,754 | - | - | - | - |
| Net income 1 | 8,771 | 13,072 | 5,002 | 11,245 | 5,210 | 6,700 | 6,481 | 4,818 | - | 4,984 | 7,514 | 6,508 | 5,079 | 11,587 | 5,770 | 7,817 | 7,150 | 5,700 | 6,450 | 7,800 |
| Net margin | 2.7% | 3.59% | 2.75% | 3.03% | 2.78% | 3.41% | 3.14% | 2.43% | - | 2.46% | 3.39% | 2.69% | 2.16% | 2.43% | 2.42% | 3.1% | 2.67% | 2.21% | 2.46% | 2.83% |
| EPS 2 | 221.5 | 330.1 | 126.3 | 284.0 | 131.6 | 169.2 | 163.7 | 121.7 | 285.3 | 125.9 | 189.7 | 164.4 | 128.2 | 292.5 | 145.6 | 201.8 | - | - | - | - |
| Dividend per Share 2 | 25.00 | 27.50 | 40.00 | 40.00 | - | 40.00 | - | 42.50 | 42.50 | - | 57.50 | - | 60.00 | 60.00 | - | 65.00 | - | 70.00 | - | 70.00 |
| Announcement Date | 1/10/20 | 1/12/21 | 1/11/22 | 1/11/22 | 4/11/22 | 7/11/22 | 10/11/22 | 1/13/23 | 1/13/23 | 4/10/23 | 7/10/23 | 10/11/23 | 1/12/24 | 1/12/24 | 4/12/24 | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: Mayo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 10,475 | 45,062 | 49,534 | 32,975 | 27,727 | 27,891 | 33,489 | 35,642 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 4,337 | 38,505 | 8,494 | -11,523 | 5,321 | 5,237 | 10,954 | 9,008 |
| ROE (net income / shareholders' equity) | 16.3% | 15.8% | 17.2% | 12.8% | 11.9% | 11.3% | 11.2% | 11% |
| ROA (Net income/ Total Assets) | 10.4% | 10.6% | 10.8% | 6.57% | 8.44% | 7.48% | 6.96% | 6.96% |
| Assets 1 | 184,233 | 201,651 | 250,683 | 352,186 | 281,952 | 334,276 | 385,393 | 415,282 |
| Book Value Per Share 2 | 3,189 | 3,679 | 4,308 | 4,811 | 5,330 | 5,842 | 6,396 | 6,990 |
| Cash Flow per Share 2 | 812.0 | 884.0 | 1,034 | 693.0 | 1,040 | 1,066 | 1,156 | 1,244 |
| Capex 1 | 29,040 | 25,948 | 26,064 | 43,497 | 46,636 | 51,157 | 48,871 | 49,129 |
| Capex / Sales | 4.75% | 3.79% | 3.59% | 5.76% | 5.63% | 5.31% | 4.66% | 4.34% |
| Announcement Date | 7/12/19 | 7/10/20 | 7/12/21 | 7/11/22 | 7/10/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
13,260
JPY
Average target price
16,603
JPY
Spread / Average Target
+25.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.83% | 3.34B | |
| -12.42% | 2.94B | |
| -27.23% | 2.92B | |
| +13.45% | 2.74B | |
| -2.25% | 1.89B | |
| +9.79% | 1.38B | |
| -20.17% | 973M | |
| -28.54% | 812M | |
| -0.53% | 462M | |
| +5.35% | 398M |
- Stock Market
- Equities
- 3349 Stock
- Financials COSMOS Pharmaceutical Corporation
